重组ProTα对肝癌小鼠Treg细胞和NKG2D阳性细胞的影响  

Influence of Proportion of Treg Cells and NKG2D-positive Cells by Recombinant ProTαin Mice Bearing Liver Cancer

作　　者：陈炜[1,2] 周克夫[3] 栗华[2] 

机构地区：[1]福建中医药大学研究生院,福建福州350108 [2]厦门大学附属第一医院,福建厦门361005 [3]厦门大学环境与生态学院,福建厦门361102

出　　处：《厦门大学学报（自然科学版）》2016年第3期456-460,共5页Journal of Xiamen University：Natural Science

基　　金：福建省自然科学基金(2013J01383);福建省医学创新课题(2009-CXB-51)

摘　　要：为观察不同时期应用重组胸腺素α原(ProTα)药物干预下肝癌荷瘤小鼠的抑瘤率,并研究其对Treg细胞和NKG2D阳性细胞的影响,将36只昆明小鼠随机分成空白组、荷瘤组、药物干预组,H22小鼠肝癌细胞皮下移植建立荷瘤小鼠模型,腹腔注射重组ProTα,观察7和14d后肝癌荷瘤小鼠的抑瘤率,并检测外周单个核细胞中调节性T细胞(Treg细胞)和NKG2D阳性细胞的比例.结果表明:移植瘤7d后,药物干预组和荷瘤组瘤质量对比无显著差异;而移植瘤14d后,药物干预组瘤质量较荷瘤组有显著减小.荷瘤14d后,荷瘤组较空白组Treg细胞比例升高,NKG2D阳性细胞比例下调,差异显著;而不论是早期药物干预组还是进展期(即移植瘤7d后)药物干预组,Treg细胞比例均显著降低,NKG2D阳性细胞显著升高.由此可见,重组ProTα能够抑制肝癌荷瘤小鼠肿瘤生长,且早期、长期用药效果更好,相关作用机制涉及下调Treg细胞数量从而抑制肝癌细胞免疫逃逸,并上调NKG2D阳性细胞数量从而提高其介导的抗肿瘤效应.To observe the tumor inhibition rate by recombinant ProTe in liver cancer-bearing mice model,and to study the influence of the proportion of Treg cells and NKG2D-positive cells, 36 Kunming mice were randomly divided into control group,tumor-bearing group and drug intervention group.Then a tumor-bearing mice model was established by transplanting H22 cells subcutaneously.By medicating recombinant ProTa through intraperitoneal injection,we observed the tumor inhibition rate after 7 days and 14 days,and detected the proportion of Treg cells and NKG2D-positive cells in PBMCs.Results showed that the difference in tumor mass between the tumor-bearing group and the drug intervention group was not significant after bearing tumor for 7 days.However,after bearing tumor for 14 days, the difference in tumor mass was significant.Additionally, the proportion of Treg ceils increased and the number of NKG2D-positive cells declined significantly in the tumor-bearing group after bearing tumor for 14 days.No matter 14 days intraper- itoneal injection of recombinant ProTa or drug intervention from the advanced stage, the proportion of Treg cells declined and the number of NKG2D-positive cells increased significantly.The results suggest that recombinant ProTa inhibits tumor growing,and the early and long-term drug intervention benefits the most. It is believed that the putative mechanism is related to that recombinant ProTa down-regulates the proportion of Treg cells,inhibiting the immune escape of hepatocellular carcinoma cells,and up-regulates the number of NKG2D-positive cells,improving the NKG2D-mediated anti-tumor effect.

关 键 词：重组胸腺素α原 肝癌 调节性T细胞(Treg细胞) NKG2D 

分 类 号：R735.7[医药卫生—肿瘤]